Missed Aveanna Healthcare's Run? What Changed Along The Way
If Aveanna Healthcare sat on your watchlist instead of in your account, the recent move may feel like a missed shot. Investors who held Aveanna Healthcare from the start of the year are up 61.6%, including dividends. That jump invites a tougher question. Back on 2026-01-01, could an investor have spotted that improving earnings visibility and liquidity might matter more than concerns about Medicaid exposure and wage pressure?
If the move has made Aveanna Healthcare harder to judge, start where the gap is still open and scan 29 high quality undervalued stocks.
The Two Futures Aveanna Healthcare Investors Had To Keep In Mind
The shares cost US$8.17 at the start of the period, and every Aveanna Healthcare holder was effectively choosing between two stories about what came next.
On the optimistic side, the improved earnings visibility view saw a Fair Value of US$8.81, a rough guide to what that thesis thought the stock was worth, built on assumptions of 7.2% annual revenue growth and profit margins reaching 6.2% over three years.
The Medicaid cuts argument put Fair Value closer to US$6, using expectations of 6.8% revenue growth, thinner 4.6% margins, and pressure from wage inflation and tighter government reimbursement.
What The Results Changed For Aveanna Healthcare
Aveanna Healthcare’s Q2 2026 report showed revenue of US$670.5 million and net income of US$40.3 million, with net margin at 6.0% versus 4.6% a year earlier. That shift in profitability supported the optimistic thesis that higher earnings visibility and liquidity would matter. Secondary offerings from major holders gave the cautious case some weight, so the evidence cut both ways.
The lesson is simple. When a thesis hinges on margin progress, track net income and margin together against the original assumptions rather than only watching headline growth or the share price.
What Aveanna Healthcare’s Run Leaves You Paying For Today
Aveanna Healthcare now trades at US$13.06, after a 61.6% gain from the start of the year. The selected Narrative’s Fair Value sits above the current price and frames today’s level as still aligned with a bullish case rather than stretched.
That view leans on execution in pediatric preferred payer penetration, integration of pediatric acquisitions, and careful use of free cash flow on a still meaningful debt load. The Narrative argues today's price does not yet fully credit sustained cash generation from AI supported back office gains and a mix shift into higher margin contracts.
"Ongoing deployment of AI and automation in billing, collections, scheduling and other back office workflows, which already coincides with record low reserve rates, recurring US$5 million to US$6 million aged accounts receivable pickups and stable or declining SG&A as a share of revenue, gives Aveanna Healthcare Holdings further scope to convert a higher portion of each revenue dollar into free cash flow and earnings even if headline EBITDA margins stay around current levels."
The price and this Narrative do not agree. → Uncover what this Narrative says Aveanna Healthcare is actually worth
How Could You Get There Earlier?
The story behind this run has already been told. The next one could be taking shape somewhere else. Where could you start looking before it becomes the headline?
- Company 1 - 31% below our estimate - converts a growing backlog of subsea opportunities into faster, higher margin services contracts.
- Company 2 - 37% below our estimate - tackles complex AI related safety and regulatory problems that blend hardware, software and human factors.
- Company 3 - 23% below our estimate - embeds AI assistants into existing productivity, developer and security tools used every working day.
Three companies from the same screener. Open every one of the 24 solid balance sheet companies →
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com